The effects of curcumin on depressive-like behavior in mice after lipopolysaccharide administration

Behavioural Brain Research

Volumn 274, Issue , 2014, Pages 282-290

  Wang, Zhen ^a   Zhang, Qingrui ^a   Yuan, Lin ^a   Wang, Shuanglian ^a   Liu, Liwei ^a   Yang, Xudong ^a   Li, Gang ^b   Liu, Dexiang ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Curcumin; Depression; Lipopolysaccharide; NF B; Pro inflammatory cytokines

Indexed keywords

CURCUMIN; CYCLOOXYGENASE 2; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MESSENGER RNA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; LIPOPOLYSACCHARIDE; SUCROSE; ANTIDEPRESSANT AGENT; PTGS2 PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; COX 2 GENE; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FORCED SWIM TEST; GENE; GENE EXPRESSION; HIPPOCAMPUS; IMMOBILIZATION; IMMUNOHISTOCHEMISTRY; INOS GENE; INTRACELLULAR SIGNALING; LOCOMOTION; MALE; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OUTCOME ASSESSMENT; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SUCROSE PREFERENCE TEST; TAIL SUSPENSION TEST; ANIMAL; BRAIN; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FOOD PREFERENCE; GENE EXPRESSION REGULATION; GENETICS; INBRED MOUSE STRAIN; METABOLISM; MOTOR ACTIVITY; NONPARAMETRIC TEST; PATHOLOGY; PSYCHOLOGY; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; CURCUMIN; CYCLOOXYGENASE 2; DEPRESSION; DISEASE MODELS, ANIMAL; FOOD PREFERENCES; GENE EXPRESSION REGULATION; HINDLIMB SUSPENSION; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED STRAINS; MOTOR ACTIVITY; NITRIC OXIDE SYNTHASE TYPE II; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; SUCROSE; SWIMMING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84906848742     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.08.018     Document Type: Article

References (53)

1. Krogh J., Benros M.E., Jorgensen M.B., Vesterager L., Elfving B., Nordentoft M. The association between depressive symptoms, cognitive function, and inflammation in major depression. Brain Behav Immun. 2014, 35:70-76.
2. Janssen D.G., Caniato R.N., Verster J.C., Baune B.T. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol. 2010, 25:201-215.
3. Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology. 2011, 36:2452-2459.
4. Kaster M.P., Gadotti V.M., Calixto J.B., Santos A.R., Rodrigues A.L. Depressive-like behavior induced by tumor necrosis factor-alpha in mice. Neuropharmacology. 2012, 62:419-426.
5. Mello B.S., Monte A.S., McIntyre R.S., Soczynska J.K., Custodio C.S., Cordeiro R.C., et al. Effects of doxycycline on depressive-like behavior in mice after lipopolysaccharide (LPS) administration. J Psychiatr Res. 2013, 47:1521-1529.
6. Jiang H., Wang Z., Wang Y., Xie K., Zhang Q., Luan Q., et al. Antidepressant-like effects of curcumin in chronic mild stress of rats: Involvement of its anti-inflammatory action. Prog Neuropsychopharmacol Biol Psychiatry. 2013, 47:33-39.
7. Garate I., Garcia-Bueno B., Madrigal J.L., Caso J.R., Alou L., Gomez-Lus M.L., et al. Stress-induced neuroinflammation: role of the Toll-like receptor-4 pathway. Biol Psychiatry. 2013, 73:32-43.
8. Brustolim D., Ribeiro-dos-Santos R., Kast R.E., Altschuler E.L., Soares M.B. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol. 2006, 6:903-907.
9. Akhondzadeh S., Jafari S., Raisi F., Nasehi A.A., Ghoreishi A., Salehi B., et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009, 26:607-611.
10. Lawson M.A., Parrott J.M., McCusker R.H., Dantzer R., Kelley K.W., O.C.J.C. Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2,3-dioxygenase-dependent depression-like behaviors. J Neuroinflammation. 2013, 10:87.
11. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res 1996, 711:163-174.
12. Ohgi Y., Futamura T., Kikuchi T., Hashimoto K. Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav. 2013, 103:853-859.
13. Buhrmann C., Mobasheri A., Busch F., Aldinger C., Stahlmann R., Montaseri A., et al. Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem. 2011, 286:28556-28566.
14. Johnson S.M., Gulhati P., Arrieta I., Wang X., Uchida T., Gao T., et al. Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anticancer Res. 2009, 29:3185-3190.
15. Menonand V.P., Sudheer A.R. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol. 2007, 595:105-125.
16. Maheshwari R.K., Singh A.K., Gaddipati J., Srimal R.C. Multiple biological activities of curcumin: a short review. Life Sci. 2006, 78:2081-2087.
17. Kulkarni S., Dhir A., Akula K.K. Potentials of curcumin as an antidepressant. ScientificWorldJournal. 2009, 9:1233-1241.
18. Bhutani M.K., Bishnoi M., Kulkarni S.K. Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes. Pharmacol Biochem Behav. 2009, 92:39-43.
19. Xu Y., Ku B.S., Yao H.Y., Lin Y.H., Ma X., Zhang Y.H., et al. Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav. 2005, 82:200-206.
20. Kulkarni S.K., Bhutani M.K., Bishnoi M. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology (Berl). 2008, 201:435-442.
21. Huang Z., Zhong X.M., Li Z.Y., Feng C.R., Pan A.J., Mao Q.Q. Curcumin reverses corticosterone-induced depressive-like behavior and decrease in brain BDNF levels in rats. Neurosci Lett. 2011, 493:145-148.
22. Xu Y., Ku B., Tie L., Yao H., Jiang W., Ma X., et al. Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Res. 2006, 1122:56-64.
23. Zhang L., Xu T., Wang S., Yu L., Liu D., Zhan R., et al. Curcumin produces antidepressant effects via activating MAPK/ERK-dependent brain-derived neurotrophic factor expression in the amygdala of mice. Behavioural brain research. 2012, 235:67-72.
24. Dumanand R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006, 59:1116-1127.
25. Guilloux J.P., Douillard-Guilloux G., Kota R., Wang X., Gardier A.M., Martinowich K., et al. Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol Psychiatry. 2012, 17:1130-1142.
26. O'Connor J.C., Lawson M.A., Andre C., Moreau M., Lestage J., Castanon N., et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry. 2009, 14:511-522.
27. Frenois F., Moreau M., O'Connor J., Lawson M., Micon C., Lestage J., et al. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology. 2007, 32:516-531.
28. Wang Z., Gu J., Wang X., Xie K., Luan Q., Wan N., et al. Antidepressant-like activity of resveratrol treatment in the forced swim test and tail suspension test in mice: the HPA axis. BDNF expression and phosphorylation of ERK. Pharmacol Biochem Behav. 2013, 112:104-110.
29. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology. 1985, 85:367-370.
30. Henry C.J., Huang Y., Wynne A., Hanke M., Himler J., Bailey M.T., et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation. 2008, 5:15.
31. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008, 9:46-56.
32. Hart B.L. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev. 1988, 12:123-137.
33. Deak T., Bellamy C., D'Agostino L.G., Rosanoff M., McElderry N.K., Bordner K.A. Behavioral responses during the forced swim test are not affected by anti-inflammatory agents or acute illness induced by lipopolysaccharide. Behav Brain Res. 2005, 160:125-134.
34. del Cerroand S., Borrell J. Interleukin-1 affects the behavioral despair response in rats by an indirect mechanism which requires endogenous CRF. Brain Res 1990, 528:162-164.
35. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology. 2005, 52:90-110.
36. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 1997, 134:319-329.
37. Tomaz V.S., Cordeiro R.C., Costa A.M., de Lucena D.F., Nobre Junior H.V., de Sousa F.C., et al. Antidepressant-like effect of nitric oxide synthase inhibitors and sildenafil against lipopolysaccharide-induced depressive-like behavior in mice. Neuroscience. 2014, 268:236-246.
38. Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008, 213:93-118.
39. Garrido-Mesa N., Zarzuelo A., Galvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol 2013, 169:337-352.
40. Rinwa P., Kumar A., Garg S. Suppression of neuroinflammatory and apoptotic signaling cascade by curcumin alone and in combination with piperine in rat model of olfactory bulbectomy induced depression. PLOS ONE 2013, 8:e61052.
41. Schneider A., Martin-Villalba A., Weih F., Vogel J., Wirth T., Schwaninger M. NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat Med 1999, 5:554-559.
42. Csaki C., Mobasheri A., Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther 2009, 11:R165.
43. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012, 36:764-785.
44. Girotti M., Donegan J.J., Morilak D.A. Chronic intermittent cold stress sensitizes neuro-immune reactivity in the rat brain. Psychoneuroendocrinology 2011, 36:1164-1174.
45. Tomaz V.S., Cordeiro R.C., Costa A.M., de Lucena D.F., Nobre Junior H.V., de Sousa F.C., et al. Antidepressant-like effect of nitric oxide synthase inhibitors and sildenafil against lipopolysaccharide-induced depressive-like behavior in mice. Neuroscience 2014, 268:236-246.
46. Muller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Muller B., et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006, 11:680-684.
47. Puntener U., Booth S.G., Perry V.H., Teeling J.L. Long-term impact of systemic bacterial infection on the cerebral vasculature and microglia. J Neuroinflammation 2012, 9:146.
48. Biesmans S., Meert T.F., Bouwknecht J.A., Acton P.D., Davoodi N., De Haes P., et al. Systemic immune activation leads to neuroinflammation and sickness behavior in mice. Mediators Inflamm 2013, 2013:271359.
49. Rothwell N.J., Luheshi G.N. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci 2000, 23:618-625.
50. Nguyen K.T., Deak T., Owens S.M., Kohno T., Fleshner M., Watkins L.R., et al. Exposure to acute stress induces brain interleukin-1beta protein in the rat. J Neurosci. 1998, 18:2239-2246.
51. Kooand J.W., Duman R.S. Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression. Curr Opin Investig Drugs. 2009, 10:664-671.
52. Wohleb E.S., Hanke M.L., Corona A.W., Powell N.D., Stiner L.M., Bailey M.T., et al. Beta-adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat. J Neurosci 2011, 31:6277-6288.
53. Hayley S., Brebner K., Lacosta S., Merali Z., Anisman H. Sensitization to the effects of tumor necrosis factor-alpha: neuroendocrine, central monoamine, and behavioral variations. J Neurosci. 1999, 19:5654-5665.